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REVIEW
Emerging Therapies and Challenges
in Spinal Muscular Atrophy
Michelle A. Farrar, PhD,1 Susanna B. Park, PhD,2 Steve Vucic, PhD,3
Kate A. Carey, PhD,1 Bradley J. Turner, PhD,4 Thomas H. Gillingwater, PhD,5
Kathryn J. Swoboda, MD,6 and Matthew C. Kiernan, DSc2
Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity ranging from progressive
infantile paralysis and premature death (type I) to limited motor neuron loss and normal life expectancy (type IV).
Without disease-modifying therapies, the impact is profound for patients and their families. Improved understanding
of the molecular basis of SMA, disease pathogenesis, natural history, and recognition of the impact of standardized
care on outcomes has yielded progress toward the development of novel therapeutic strategies and are summarized.
Therapeutic strategies in the pipeline are appraised, ranging from SMN1 gene replacement to modulation of SMN2
encoded transcripts, to neuroprotection, to an expanding repertoire of peripheral targets, including muscle. With
the advent of preliminary trial data, it can be reasonably anticipated that the SMA treatment landscape will transform
significantly. Advancement in presymptomatic diagnosis and screening programs will be critical, with pilot newborn
screening studies underway to facilitate preclinical diagnosis. The development of disease-modifying therapies will
necessitate monitoring programs to determine the long-term impact, careful evaluation of combined treatments, and
further acceleration of improvements in supportive care. In advance of upcoming clinical trial results, we consider the
challenges and controversies related to the implementation of novel therapies for all patients and set the scene as
the field prepares to enter an era of novel therapies.
ANN NEUROL 2017;81:355–368
Spinal muscular atrophy (SMA) is characterized bymuscle weakness and severe physical disability attribut-
ed to motor neuron degeneration in the spinal cord and
brainstem. It continues to represent the leading genetic
cause of infant death attributed to respiratory insufficiency,
with a pan-ethnic incidence of approximately 1 in 11,000
live births and a carrier frequency of 1 in 40 to 67.1 The
most common form of SMA is caused by mutations in
the survival motor neuron 1 (SMN1) gene, resulting in
SMN protein deficiency.2 The almost identical survival
motor neuron 2 (SMN2) gene produces a small amount
of functional SMN protein, and SMN2 copy number is
recognized as a major modulator of the SMA phenotype.3
There have been significant advances in the understanding
of the underlying pathogenic process in SMA. Concomi-
tantly, there has been progress in defining disease progres-
sion and natural history, with a concerted effort in
developing outcome measures and clinical trial readiness.
Consequently, novel genetic therapies, aimed at modulat-
ing SMN protein expression, have resulted in significant
clinical improvement in SMA patients for the first time,
thereby providing much needed hope for the treatment of
this devastating disease. As such, the present review will
focus on recent advances made toward developing novel
therapeutic strategies and future challenges as the field
enters into a new treatment era.
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Progress in Understanding the Natural
History of SMA
SMA has a broad range of age of onset, severity, rate of
progression, and variability between and within subtypes
(Table 1).4,5 In type I SMA, earlier age of onset is associ-
ated with worse prognosis and mortality6; the median
age to death or ventilation (>16 hours per day) is 13.5
months and 10.5 months for patients with 2 copies of
SMN2.5 Patients with SMA type II have a better progno-
sis than those with type I disease, with 93% surviving to
25 years.6 After age 15, a relative stability in function
develops with subsequent gradual decline over time.7 Age
of onset is also a predictor of functional ability, with
patients classified as SMA IIIa having a 73% probability
of walking 10 years after diagnosis, whereas SMA type
IIIb patients have a 97% probability of walking 10 years
after diagnosis.8
A better understanding of the natural history of
SMA has been crucial to the development of relevant
outcome measures and implementation of clinical trials.
Understanding variability in the rate of clinical progres-
sion in SMA related to age, SMA type, and ambulation
status will assist in the development of appropriate motor
function scales that are able to monitor subtle, but clini-
cally meaningful changes (see Finkel et al9). The clinical
heterogeneity in motor function is a challenge and con-
nected with the range of possibilities for change in short
time frames. The pattern of age-related changes in motor
function in SMA types II and III is nonlinear, and there
are different patterns of progression between ambulant
and nonambulant patients.7,10 In nonambulant patients,
variable improvement in motor function occurs up to 4
to 5 years of age, before functional ability (eg, in upper
limbs) declines between 5 and 15 years. After age 15, a
relative stability in function develops with subsequent
gradual decline over time.7 Decline in motor and respira-
tory function within a 12-month period was often minor,
although progression was variable between individuals.7,9
This slow rate of progression, particularly in milder phe-
notypes, poses a major challenge to clinical trials in SMA
because most trials need to be completed within 1 to 2
years. Rather than SMA phenotype, ambulant status may
be more relevant to the trajectory of disease progression
and consequently in trial design and outcome measure
development. For instance, different outcome measures
are required to monitor clinically important differences
among ambulant and nonambulant cohorts, yet it will
also be important to better connect scales that measure
different functional levels to be able to more accurately
demonstrate improvements.10
In addition to motor function scales, neurophysio-
logical studies have provided insights into clinical pro-
gression, timing of motor neuron loss, and compensation
in SMA; however, these studies have predominantly
focused on later stages of disease. Electrophysiological
outcomes compound muscle action potential (CMAP)
amplitude and motor unit number estimation (MUNE)
correlate with age, SMA type, functional status, and
TABLE 1. Classification and Subtypes of Spinal Muscular Atrophy
Type Age of Onset Maximal
Motor
Milestone
Motor Ability and
Additional Features
Prognosisc
SMA 0 Before birth None Severe hypotonia;
unable to sit or rolla
Respiratory insufficiency at
birth; death within weeks
SMA I 2 weeks (Ia)
3 months (Ib)
6 months (Ic)
None Severe hypotonia;
unable to sit or rollb
Death/ventilation by 2 years
SMA II 6 to 18 months Sitting Proximal weakness;
unable to walk independently
Survival into adulthood
SMA III <3 years (IIIa)
>3 years (IIIb)
>12 years (IIIc)
Walking May lose ability to walk Normal life span
SMA IV >30 years or 10 to 30 years Normal Mild motor Impairment Normal life span
aNeed for respiratory support at birth; contractures at birth, reduced fetal movements.
bIa joint contractures present at birth; Ic may achieve head control.
cPrognosis varies with phenotype and supportive care interventions.
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SMN2 copy number.11 Gradual decline in motor and
respiratory function may, in part, be related to physical
growth in SMA types II and III, with the provision that
CMAP amplitude remains stable.9 In addition, the CMAP
amplitude may also remain constant despite reduction in
MUNE values, a finding explained by the presence of
motor unit loss with compensatory collateral sprouting
and supported by axonal excitability studies.12 Transcranial
magnetic stimulation techniques assessing central motor
networks also suggest adaptive changes.13 Neurophysiolog-
ical studies are rare in presymptomatic infants, but suggest
that motor function is initially relatively preserved.11,14 In
SMA type I, this loss of motor function is followed by
early and precipitous reductions in CMAP and MUNE
responses. The onset, time course, and extent of motor
neuron loss has not been established in SMA types II and
III, yet is important in determining whether there is a spe-
cific therapeutic window. Preclinical studies of SMN
restoring therapies, such as gene therapy and antisense oli-
gonucleotides to correct SMN2 messenger RNA (mRNA)
splicing, provide support for the utilization of electrophysi-
ological biomarkers for treatment stratification, determin-
ing response and defining therapeutic windows.15
Clinical Care
In parallel with preclinical advances, continued improve-
ments in multidisciplinary care and technological advan-
ces have altered the natural history of SMA since the
Consensus Statement for standards of care in SMA was
published in 2007 (Table 2; Appendix 1)16; however,
TABLE 2. Current Management of Spinal Muscular Atrophy
Assessments Interventions
Respiratory Cough effectiveness; respiratory muscle func-
tion tests; overnight oximetry; forced vital
capacity (>6 years)
Overnight polysomnography if disordered
breathing suspected
Acute respiratory infections
Referral to respiratory specialist
Routine immunizations
Annual influenza vaccination
Airway clearance techniques and cough assis-
tance—chest physiotherapy, postural drainage,
mechanical or manual cough assistance
Noninvasive ventilation (nocturnal and/or day-
time if indicated)a
Antibiotics intensified airway clearance,
increased ventilation supporta
Gastrointestinal
and nutritional
Feeding and swallowing assessment
Assess caloric intake
Assess for signs of reflux or aspiration
Assess for constipation
Nutritional supplementation, modifying food
consistency, optimizing oral intake, positioning
and seating alterations
Nasogastric, nasojejunal, or percutaneous gas-
tronomy—as soon as reduced oral intake is
recognized
Nissen fundoplication (if indicated)
Hydration, regular oral aperients
Orthopedic and
rehabilitation
Posture, mobility, function
Contractures
Scoliosis
Hip subluxation/dislocation
Equipment to assist with mobility, self-care,
and function
Physiotherapy, standing frames, orthoses
Spinal surgeryb
Psychological Assess for depression/anxiety Counseling, pharmacotherapy
The management of SMA incorporates a multidisciplinary and supportive approach, including neurologists (adult and pediatric), respiratory physi-
cians, geneticists, gastroenterologists, palliative care physicians, rehabilitation specialists, orthopedic surgeons, and allied health.
aThe appropriate level of interventional support to prolong life, particularly in SMA type1, is controversial and the consensus statement16 recog-
nizes the importance of discussions with the family to explore and define potential quality-of-life and palliative care issues. The philosophy and
introduction of proactive respiratory support in patients with SMA type 1 varies considerably and practice varies internationally.
bThere is no consensus on management of scoliosis or hip subluxation/dislocation in nonambulant patients.
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even in areas of general consensus, marked variability in
the implementation of the standards of care, particularly
in the use of ventilation, nutritional support, and scolio-
sis surgery, have been observed.17,18 For patients partici-
pating in clinical trials, it is crucial to standardize the
management of modifiable factors, particularly nutrition
and respiratory support, given that differences in care
practices may impact outcome. However, at the most
severe end of the SMA phenotypic spectrum, in the set-
ting of uncertain therapeutic efficacy, this remains a chal-
lenge. Advances in drug development are likely to impact
the standards of care for SMA, particularly given that
successful disease modification will inevitably alter natu-
ral history and necessitate new standards of supportive
care and interventions.
Respiratory Management
Respiratory complications are the major cause of morbid-
ity and mortality in SMA. The onset of peripheral hypo-
ventilation may be asymptomatic and initially occur
during sleep, but with deterioration daytime respiratory
dysfunction develops. Objective measures of respiratory
function are not routinely performed in children younger
than 4 to 6 years because of complexity of the required
maneuvers; potential alternative measures of respiratory
function, for example, sniff nasal inspiratory pressure and
forced oscillation techniques, have been proposed in this
population because they are noninvasive and require less
patient cooperation.19 Attempts to identify nighttime
hypoventilation using pulmonary testing in SMA patients
have been largely unsuccessful,20 highlighting the contin-
ued benefit of overnight polysomnography. Assessment
frequency needs to be individualized, based on current
functional status and rate of disease progression, and
should be supplemented with other clinical observations,
such as assessment for paradoxical breathing and chest
wall growth, among others.
The major respiratory complications faced by SMA
patients include impaired cough—resulting in reduced
clearance of lower airway secretions—hypoventilation,
chest wall and lung underdevelopment, and recurrent
infections that exacerbate muscle weakness. Although
contentious, proactive management with noninvasive
ventilation, even before the onset of paradoxical respira-
tions, has led to improved survival, prevention, and
improvement in chest wall deformity as well as improved
quality of life.21,22 In addition, optimizing airway clear-
ance is important for acute and chronic management of
SMA patients with secretion mobilization techniques,
such as assisted coughing,23–25 physiotherapy, and postur-
al drainage.26 The decision to progress to invasive venti-
lation with tracheostomy remains an ethical dilemma,
and considerable variability exists between countries with
no consensus in guidelines.17,18 The goal of interventions
should always be to improve quality of life with the pro-
vision of support and assistance to parents in making dif-
ficult decisions consonant with their values and beliefs.
Nutritional Support
Malnutrition is prevalent in SMA, with bulbar dysfunc-
tion and deterioration of nutritional status preceding and
exacerbating respiratory failure with disease progres-
sion.27,28 Appropriate nutritional management of SMA
patients is critical for improving quality of life and opti-
mizing survival,29 although no clear consensus exists on
the timing of initiation of nutritional support.
Orthopedic Considerations
Scoliosis is a common complication of SMA, present in
60% to 95% of patients, secondary to progressive muscle
weakness. In SMA types I and II, scoliosis occurs earlier
and a more-severe, progressive curvature is evident com-
pared to SMA type III.30 Progression of scoliosis may
exacerbate respiratory dysfunction, gastrointestinal reflux,
and increase postural discomfort.30 Management of scoli-
osis includes nonsurgical options, such as physical thera-
py, bracing, and seating modification, and depending on
the strategy used, may slow, but not necessarily prevent,
curve progression. Additionally, surgical approaches are
utilized in progressive scoliosis, most frequently in type
II and III SMA. Posterior spinal fusion is typically imple-
mented after skeletal maturity during adolescence in
SMA, with iliac fixation used to assist correction of pel-
vic obliquity. Innovative surgical techniques utilizing
growing rods (eg, vertical prosthetic titanium rib or mag-
netic rods) enable spinal growth while avoiding repeated
invasive surgeries; however, medium- to longer-term
implications remain unclear. Although surgery does not
reverse the respiratory reserve lost because of scoliosis, it
leads to improved life quality31 and can slow deteriora-
tion of respiratory function.32 Finally, with an intrathe-
cally administered therapy showing promise in phase 3
clinical trials, construction of bony windows may be con-
sidered to facilitate drug administration.
Genetic and Environmental Insights
Into Pathogenesis
Whereas mutations in SMN1 characterize SMA, disease
severity is also linked to a number of genetic modifiers.
These modifiers are of relevance in enabling patient strat-
ification in clinical trials, better prediction of an individ-
ual’s prognosis, and establishing newborn screening.
Patients have variable copy numbers of the SMN2 gene,
a related gene that differs from SMN1 by only five
ANNALS of Neurology
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nucleotides, altering splicing and leading to transcription
of a nonfunctional SMN protein lacking exon 7 in the
majority of transcripts (Fig 1).33 SMN2 copy number is
the main determinant of phenotype, although not solely
sufficient to predict severity.34 Sequence variations within
the SMN2 gene and upregulation of modifier proteins,
such as plastin 3, may also positively modify pheno-
type.35–37 In addition, nutritional deficiency, oxidative
stress, and hypoxia, partly attributed to gastrointestinal
dysfunction, may cause widespread splicing alterations,
including SMN2, and accelerate SMA progression.38–40
How Low Levels of SMN Cause SMA
Recent insights into the role of SMN within motor neu-
rons have furthered our understanding of the implica-
tions of SMN deficiency.41 The best characterized role of
the SMN complex is in the assembly of Sm proteins (a
distinctive family of RNA associated small proteins) onto
small nuclear RNAs (snRNAs), forming small nuclear
ribonucleoproteins (snRNPs), which are essential compo-
nents of pre-mRNA splicing machinery in cells.42 SMN
deficiency and therefore reduced snRNP assembly capaci-
ty are proposed to cause aberrant splicing or transport of
RNPs to the detriment of motor neurons.43 A recent
study showed transcriptional dysregulation in motor neu-
rons isolated from very young presymptomatic SMA mice
that preferentially affected a small subset of genes involved
in synaptogenesis and maintenance of neuromuscular junc-
tions (NMJs).43 Furthermore, some of these dysregulated
motor neuron relevant genes showed underlying splicing
changes, strengthening a potential link between aberrant
splicing and motor neuron vulnerability.43
A second view of SMA pathogenesis contends that
SMN has axonal function independent of splicing that
may be disrupted in SMA. Consequently, SMN deficien-
cy may impair targeting and local translation of axonal
mRNAs essential for motor neuron development and
maintenance.44,45 Furthermore, SMN regulates several
other fundamental cellular processes in the neuronal
cytoplasm that are critical for maintaining axonal and
synaptic health, including endocytic pathways, local
translation, mitochondrial transport, and targeting to
axons and ubiquitin homeostasis.46–51
FIGURE 1: Genetics of Spinal Muscular Atrophy. In humans, the SMN protein is encoded by the SMN1 and SMN2 genes. The
C to T substitution in exon 7 of SMN2 is translationally silent, but alters splicing such that the majority of SMN2 transcripts
lack exon 7 and the truncated protein is unstable. Normally, SMN1 produces abundant SMN protein. In SMA, homozygous
mutation of SMN1 results in only a small amount of functional SMN protein contributed by the varying copy numbers of
SMN2. mRNA 5 messenger RNA; SMN 5 survival motor neuron [Color figure can be viewed at wileyonlinelibrary.com].
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Animal Models of SMA
Current understanding of SMA pathogenesis has been
generated largely as a result of the availability of mouse
models of SMA. These have been largely generated by
targeting the endogenous mouse Smn gene, while using
transgenic strategies to add variable copy numbers of the
human SMN2 transgene.52 These animal models tend to
phenocopy severe forms of the human disease, resulting
in the majority of animal-based work focusing on early
postnatal phenotypes. Recently, alternative strategies have
been used to generate mice modeling less-severe forms of
SMA, allowing investigation of disease pathogenesis and
preclinical drug testing more relevant to type II and III
SMA.53,54 Additional animal models of SMA are also
beginning to play an important role in SMA research,
including Drosophila and zebrafish,55,56 and recent devel-
opments suggesting that large animal models (eg, pigs)
may be forthcoming.57
Although alpha motor neurons in the spinal cord
remain the primary pathological target in SMA,58 there is
now accumulating evidence suggesting that other cells,
tissues, and organs contribute to disease symptoms
(Fig 2).59,60 For example, there is now experimental evi-
dence suggesting a non-cell-autonomous contribution to
motor neuron degeneration from astrocytes and Schwann
cells.61,62 Likewise, low levels of SMN in skeletal muscle
have been implicated in SMA pathogenesis with significant
disruption of the molecular composition of skeletal muscle
evident in presymptomatic severe SMA mice in the absence
of detectable changes in lower motor neurons.63 One
potential unifying factor may be a deficiency in the devel-
opment of vasculature in SMA; the resulting hypoxia would
likely impact motor neurons as well as skeletal muscle and
possibly contribute to the gastrointestinal defects (gastro-
esophageal reflux, constipation, and delayed gastric empty-
ing) commonly observed in SMA patients.64Although the
mechanisms mediating the effects of vascular depletion have
not been fully elucidated, hypoxia has been identified as a
modifier of SMN2 splicing, potentially explaining some of
the splicing alterations observed in SMA.38,39,65
Disease-associated phenotypes have been reported
across a range of other organs in SMA mice (in some
FIGURE 2: Pathophysiological findings in SMA. Multiple functional abnormalities in motor networks have been identified in SMA
mice and humans, including defects in astrocytes, Schwann cells, motor neurons, and skeletal muscle. Disease-associated pheno-
types have also been reported across a range of other organs in SMA mice (in some cases supported by data from human
patients), including cardiac structural and functional abnormalities, gastrointestinal tract dysfunction, and irregular bone remodel-
ing. One potential unifying factor may be a deficiency in the development of vasculature in SMA, with the resulting hypoxia like-
ly impacting a range of cell types. SMA 5 spinal muscular atrophy. [Color figure can be viewed at wileyonlinelibrary.com]
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cases supported by data from human patients). These
include functional and structural cardiac defects,66 abnor-
mal development of the gastrointestinal tract, liver, and
spleen,64,67,68 and irregular bone remodeling and skeletal
pathology.69 These findings suggest that successful treat-
ment of SMA may require systemic targeting of a range
of affected tissues. However, how these findings will
translate to humans is uncertain, for example, heart
defects are rare in humans.
Defining the Therapeutic Window
in Animal Models
In severe SMA mice, induction of SMN expression at
gestation or in the early postnatal period substantially
improves survival, whereas later induction is less effec-
tive.70,71 Mice are resistant to SMN depletion after early
postnatal stages, suggesting that there is a period of sensi-
tivity to low SMN levels and that high SMN levels are
required during this early postnatal stage.70,72 Notably, in
mouse models, the time period when SMN function is
required coincides with the neonatal period of NMJ
establishment, development, and maturation, suggesting
that the mechanistic underpinnings of the therapeutic
window are based on the pathways driving normal NMJ
maturation. These observations imply that early correc-
tion of SMN levels in SMA types II and III is likely to
be necessary and sufficient to protect the neuromuscular
system, and lifelong expression of SMN may not be
required.
Whereas most preclinical studies investigating SMN
restoration in animals were limited to evaluating pre-
symptomatic administration of gene therapy with viral
vectors or antisense oligonucleotides to correct SMN2
splicing and enhance SMN expression, which, in most
cases, robustly improves the health of SMA mice, some
studies have tested the impact of pre- and postsympto-
matic SMN restoration. Systemic delivery of these
approaches largely rescued SMA mice’s motor function,
neuromuscular physiology, and life span when delivered
within the first 3 postnatal days (P0–P3), but were less
effective beyond P5 and gene therapy was not effective at
P10, confirming the presence of a narrow therapeutic
window.73,74 However, SMN restoration using intrave-
nous injection of self-complementary adeno-associated
virus (scAAV9)-SMN vectors given at symptom onset
had a marked effect with amelioration of severe proximal
weakness and electrophysiological indices, in a porcine
model of SMA57 which may represent a more-relevant
model for predicting efficacy in humans. Even so, pre-
symptomatic delivery prevented the development of
symptoms, suggesting that therapeutic windows are still
critical in this model. Whereas it is accepted that animal
models cannot recapitulate human SMA precisely, the
translation of concepts of motor neuron degeneration to
humans suggests that presymptomatic or early-
symptomatic restoration of SMN (during NMJ matura-
tion) will likely produce the best response to therapy. An
unresolved issue remains as to whether commencing ther-
apy in older patients will be effective. The time course
and extent of motor neuron loss in type III or IV has
never properly been mapped, largely attributed to a pau-
city of robust animal models of less-severe forms of
SMA. Encouragingly, recent results from models of
milder SMA phenotypes suggest that some therapeutic
efficacy may be possible even at late disease stages.75
Although the therapeutic window for SMA types III and
IV has not been defined, the normal early motor devel-
opment may suggest that it is linked to age of presenta-
tion and broader than types I and II. Preliminary clinical
trial data are emerging and indicating that with SMN
repletion motor neurons may not be irreversibly doomed.
However, animal models recapitulating severe SMA show
rapid postnatal motor neuron attrition and reduced effi-
cacy with delayed treatments, such that the optimal suc-
cess may ultimately arise from presymptomatic provision
of therapy.73,76
Therapeutic Developments
The pipeline of therapies for SMA encompasses four dif-
ferent strategies, including SMN1 gene replacement,
modulation of SMN2 encoded full-length protein levels,
neuroprotection, and targeted improvements of muscle
strength and function (Fig 3). Translational research con-
tinues to progress and clinical trials have recently report-
ing positive preliminary results related to safety and
efficacy of the newest approaches (Table 3). This follows
a number of negative clinical trials of repurposed drugs,
including valproic acid and acetyl-L-carnitine, phenylbu-
tyrate hydroxyurea, riluzole, and somatotropin,77–79
despite promising preclinical data. Importantly, these
negative studies have informed clinical trial design, vali-
dated the reliability and feasibility of specific outcome
measures, and highlighted the importance of patient
stratification.
In a mouse model of severe SMA, postnatal intrave-
nous gene therapy using a viral vector rescued motor
function and neurophysiology and extended survival
from 2 weeks to beyond 250 days.70 A phase 1/2a clini-
cal trial for AVXS-101(a self-complementary AAV9 carry-
ing the SMN gene under the control of a hybrid
cytomegalovirus enhancer/chicken-b-actin promoter) in
SMA type I infants has completed enrollment and initial
observations in safety, survival, and motor function have
been promising with all patients event free (death or
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continuous noninvasive ventilation greater than 16 hours
per day) and stabilization of pulmonary outcomes
reported.80 Modest improvements in motor function
were observed in patients receiving a low dose of the
study drug and greater improvements were shown in
patients receiving the proposed therapeutic dose; 2
patients achieved normal motor function 4.9 and 10.3
months following treatment as measured by the Child-
ren’s Hospital of Philadelphia Infant Test of Neuromus-
cular Disorders (CHOP-INTEND), a marked change
from the natural history of SMA type I.81
The most advanced compound known to increase
production of fully functional SMN protein is nusinersen
(IONIS-SMNRX), an antisense oligonucleotide adminis-
tered intrathecally that modifies the splicing of SMN2. A
phase 1 open label study of nusinersen in 28 SMA II
and III patients aged 2 to 14 years reported that the
drug was well tolerated with no safety concerns identi-
fied.82 Transient back pain and postlumbar puncture
headache were of a similar frequency to previous reports
in infants and children undergoing lumbar puncture.
Favorable time- and dose-dependent increases in muscle
FIGURE 3: Therapeutic targets for SMA being investigated in clinical trials. SMN1 gene replacement therapy utilizes a self-
complementary adeno-associated viral vector (AAV9-SMN) that crosses the blood–brain barrier following intravenous administra-
tion. Compounds that increase the production of fully functional SMN protein by modifying the splicing of SMN2 include the
orally available small molecules, RG7916 and LMI070, and the intrathecally administered antisense oligonucleotide, nusinersen,
which acts by displacing heterogenous nuclear ribonucleoprotein (hnRP) proteins from the intronic splicing silencer site on the
SMN2 pre-mRNA. The neuroprotective effects of olesoxime, through altered mitochondrial permeability, and exercise, through
greater motor neuron survival, maintenance of neuromuscular junctions, and improved neuromuscular excitability properties, are
being investigated. Additional strategies focused on improving neuromuscular function and physical performance include CK-
2127107, a fast skeletal troponin activator that sensitizes the sarcomere to calcium and increases the contractile response to
nerve signaling, and 4-aminopyridine and pyridostigmine that may facilitate neurotransmitter release and increase its synaptic
duration. mRNA 5 messenger RNA; SMN 5 survival motor neuron. [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 3. New Therapeutic Approaches in Spinal Muscular Atrophy: Current Clinical Trials
Approach Study Description Preliminary Results
SMN1 gene replacement
AVXS-101a,b Phase 1/2a gene transfer of SMN1 in SMA
type I infants
Two cohorts treated with a single dose of
AVXS-101 delivered intravenously
Safety, survival, and motor function have been
promising with all patients event free (death or
continuous noninvasive ventilation greater than
16 hours per day) and stabilization of pulmonary
outcomes.80
Modulation of SMN2 full-length protein
Nusinersen (IONIS–SMNRX)
a 10 phase 1 to phase 3 studies
Nusinersen administered by intrathecal
injection in SMA type I infants (0–6
months) and later-onset type II/III partici-
pants (age range, 2–14 years)
Favorable safety, tolerability, and encouraging clin-
ical efficacy83,84; intrathecal administration tolerat-
ed, no drug-related adverse events82
Phase 3 ENDEAR study in SMA type I and
phase 3 CHERISH study in childen aged 2 to 12
years with SMA type II; primary endpoint met in
each study at interim analysis with statistically sig-
nificant improvement in motor milestones
RG7916 (RO7034067) Phase 2 in adult and paediatric patients
with type II and III SMA with oral
delivery
LMI070 Phase 1/2 study in infants with type I
SMA (1–7 months) of oral LMI070
Neuroprotection: promote survival of motor neurons
Olesoxime (TRO19622) Phase 2 studies in 3- to 25-year-olds with
type II or nonambulant type III SMA
A greater percentage of patients were stable or
improved compared with placebo; however, the
primary endpoint was not met (p 5 0.07).89
Exercise Pilot study of a physiotherapeutic approach
tailored to type II and III SMA patients
aged 5 to 10 years
Exercise Muscle-strengthening program using hand
weights and resistance bands in combina-
tion with a home-based cycle ergometry in
type III patients aged 8 to 50 years
Enhancing Nerve or Muscle Function
CK-2127107 A phase 2 oral compound in SMA type II
to IV (aged 12 years1).
Pyridostigmine Phase 2 study in SMA type III (aged 6
years1)
4-aminopyridine Phase 2/3 study assessing changes in walk-
ing ability and endurance in 18- to 50-
year-olds with SMA type III
aAVXS-101 and Nusinersen have been granted US Food and Drug (FDA) and European Medicines Agency orphan drug status and FDA fast-track
approval.
bAVXS-101 has been granted FDA Breakthrough Therapy Designation. Following a FDA Type B meeting on September 30, 2016, a single-arm
pivotal trial has been announced.
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function were reported in patients 9 to 14 months post-
dosing.83 Observations from a phase 2 open-label study
of nusinersen in 20 infants with SMA type I show
increases in motor function, ranging from stable inde-
pendent sitting to walking (the latter patients having 3
copies of SMN2, not the standard type I SMA copy
number of 2), with no evidence of a therapeutic plateau
in motor skills yet.84 Interim analyses of phase 3 clinical
trials evaluating nusinersen, including infants with SMA
type I (ENDEAR) and children with SMA type II
(CHERISH), have reached primary endpoints with
improvement in motor milestones and favorable safety
profiles. Regulatory filings have recently been submitted
and an expanded access program initiated for SMA type
I. The effect of presymptomatic administration of nusi-
nersen is currently being evaluated and will provide piv-
otal insights into therapeutic windows. Further advances
include the development of peptide-mediated oligonu-
cleotides to enable systemic therapy and overcome diffi-
culties with central nervous system delivery by repeated
intrathecal injections, with recent efficacy demonstrated
in rodent models.85
Orally bioavailable small molecules are being devel-
oped for selective SMN2 splicing correction, and several
(RG 7916 and LM1070) are entering early phase clinical
trials. Administration of these compounds to mice with
severe SMA increased SMN protein levels, motor func-
tion, and survival (from 18 to beyond 150 days).76,86
Further clinical trials are also needed to define the effica-
cy of salbutamol, a b agonist that promotes exon 7 inclu-
sion in SMN2 transcripts, following encouraging early
results from several pilot studies in SMA patients.87
Increasing the expression of SMN2 with small molecules,
such as quinazoline-derived compounds, moderately
increased SMN mRNA and protein levels as well as sur-
vival in severe SMA mice.88 However, plans to progress
beyond phase 1 clinical trials have been terminated,
reflecting challenges in translating disease-modifying ben-
efits from mouse to human.
Olesoxime has entered clinical trials in SMA
patients following demonstration of its neuroprotective
properties motor neurons in cell culture and SMA mice.
Phase 2 trials have been completed and though the pri-
mary endpoint was not statistically significant, a greater
percentage of patients were stable or improved compared
to placebo, suggesting that olesoxime may slow decline
in motor function over 2 years in already symptomatic
patients with SMA types II and III.89 However, further
data are needed to determine whether this is a clinically
meaningful effect.
Additional strategies focused on improving neuro-
muscular function and physical performances in SMA
patients are also being assessed in clinical trials. Among
these is CK-2127107, which slows calcium release from
fast skeletal muscle troponin and sensitizes the sarcomere
to calcium thus increasing contractile response to nerve
signalling; studies have demonstrated its efficacy in
mouse models of motor neuron disease and it appears
safe in healthy human volunteers.90 Additionally,
exercise-induced neuroprotection has recently been dem-
onstrated in SMA-like mice with greater motor neuron
survival, maintenance of neuromuscular junctions, and
improved neuromuscular excitability properties, accompa-
nied by positive metabolic and behavioral changes.91 The
benefits and risks of different types of exercise are being
evaluated in SMA patients, and initial studies have dem-
onstrated that resistance training is feasible, safe, and well
tolerated and aerobic training increases oxidative capaci-
ty.92,93 Further outcomes will be important in planning
patient therapy and rehabilitation.
A number of potential SMN independent therapeu-
tic targets have been identified in preclinical studies.
These include the compounds, Fasudil and Y-27632, that
regulate actin cytoskeleton integrity through Rho-
associated protein kinase inhibition,94,95 the antioxidant
flavonoid, quercetin, that suppresses beta-catenin signal-
ing,96 BAY 55-9837 that indirectly stabilizes SMN
mRNA,97 and compounds that activate the mammalian
target of rapamycin pathway.98 In addition, RNA
sequencing of motor neurons may identify novel down-
stream targets of splicing alterations. Stabilization of
endogenous SMN protein provides a further therapeutic
strategy, with STL-182 showing promising preclinical
efficacy.99
Conclusions and Future Directions
There have been tremendous advances in therapeutic
development in SMA, with treatment options rapidly
evolving and preliminary results of clinical trials in
patients producing new hope. In parallel, there has been
substantial progress in understanding clinical disease pro-
gression and natural history to accelerate the implemen-
tation of clinical trials. Rodent models suggest that
requirements for normal SMN levels are paramount dur-
ing development of the motor unit, with SMN restoring
therapies most effective early. The translation of these
concepts to humans is needed to determine whether ther-
apy in later stages of disease is beneficial. Critical for
timely access to novel disease-modifying treatments is the
rapid recognition of clinical manifestations and diagnosis,
with presymptomatic diagnosis to guard against disease
onset and progression the ultimate aim. Population-based
newborn screening pilot programs are determining the
feasibility and reliability of presymptomatic diagnosis,
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and effective molecular methods have been validated on
dried blood spots, including real-time polymerase chain
reaction and high-resolution melting analysis.100–103
Improvements in multidisciplinary clinical care,
together with advances in technology, have changed the
natural history for patients with SMA. With new thera-
peutics emerging, it is likely that profound shifts in man-
agement approaches will transpire in severe SMA. These
will also necessitate additional validation of nonmotor
standardized and reliable outcome measures, particularly
respiratory assessments, given that these are functionally
meaningful and contribute substantially to morbidity.
Secondary complications, such as scoliosis and contrac-
tures, may further limit the value of existing motor out-
come measures. Furthermore, individual motor function
scales are relevant to specific levels of SMA severity, and
it will be important to better connect scales that measure
different functional levels to be able to more accurately
demonstrate improvements. Whereas motor function
scales are a major focus and most relevant to SMA,
strength testing, electrophysiological assessments, and
metabolomic and proteomic outcomes measures are also
being integrated into natural history studies and clinical
trials in SMA.104
With the tantalizing prospect of novel therapies
moving closer to clinical reality, more questions arise,
compelling the formation of collaborative and linked
future monitoring programs to determine the impact of
these therapies. Longer-term monitoring programs should
also include assessments of cognition, growth, autonomic
function, and adverse events and enable a comparison
and evaluation of combined treatments. These will serve
to understand how novel therapies may affect phenotype
over the longer term and the duration of effect—will
they reduce progression, as well as stabilize or improve
function? How will they affect requirements for perma-
nent ventilation or age of death? What is the potential
variability of responsiveness of different motor neuron
subpopulations attributed to drug distribution or inher-
ent differences in reversibility? Furthermore, the possibili-
ty that reinnervation may stress remaining motor
neurons, resulting in a post-polio-like condition with late
deterioration, must be considered. It is likely that com-
bined therapies increasing SMN levels while also enhanc-
ing and preserving neuromuscular function and
preventing additional systemic pathology will provide the
best approach. In the setting of a first-in-class approved
therapy, continued progress in developing second-
generation and combination therapies will require inno-
vative approaches in trial design. In addition, new chal-
lenges are arising with emerging therapies, including
difficulties with access to treatment associated with the
complexities, costs, and expertise required with intrathe-
cal administration. Further efforts to ascertain optimal
routes of drug delivery and distribution and defining the
therapeutic window will be essential.
As the field looks toward a new treatment era, it is
necessary to focus on timely access to novel, disease-
modifying therapy and endeavoring to develop therapies
for patients with SMA of all ages and severities.
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